Reed Jobs would rather talk about curing cancer than his last name

July 11, 2026 Connie Loizos

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs' words, a huge part of what Yosemite does. "I didn't expect Yosemite to be moving this fast," he said.

Previous Article
TechCrunch Mobility: A robotaxi ultimatum
TechCrunch Mobility: A robotaxi ultimatum

Welcome back to TechCrunch Mobility, your hub for the future of transportation and now, more than ever, how...

Next Article
This slushie machine was a lifesaver during NYC’s heat wave
This slushie machine was a lifesaver during NYC’s heat wave

Ninja's latest slushie machine builds on the popularity of the original Slushi, but with a big upgrade.